Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
March 04, 2021 16:15 ET
|
Onconova Therapeutics, Inc.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 NEWTOWN, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a...
Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
March 01, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
February 24, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option
February 16, 2021 16:03 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
February 16, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
February 10, 2021 16:01 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
January 14, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
December 21, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
November 23, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021China Phase 1 trial enrollment ongoingKey regulatory milestone achieved to enable further study of product candidate for...
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 12, 2020 16:05 ET
|
Onconova Therapeutics, Inc.
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumorsInvestigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS...